Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025
Oncology Research and Treatment · 2026
DOI: 10.1159/000551042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, 2026. Verfasst von Elisabeth Tregel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Campus Benjamin Franklin, Universitätsmedizin Berlin, Freie Universität Berlin and Humb…. Hauptthemen laut MEDLINE: Neoplasms, Medical Oncology, Translational Research, Biomedical, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
The ESMO Congress 2025 in Berlin marked a milestone in precision oncology with the introduction of the first dedicated tumor-agnostic track, reflecting the shift from organ-based to molecularly defined cancer therapy. Across multiple sessions, updated data on biomarker-driven and pathway-based treatments demonstrated how targeted therapies can transcend histologic boundaries. Highlights included long-term results for approved tumor-agnostic agents (e.g., NTRK and BRAF-directed therapies, HER2-targeted antibody-drug conjugates [ADCs], as well as next-generation KRAS inhibitors, HER2- and TROP2-directed tyrosine kinase inhibitors and ADCs, and novel targets such as MTAP deletions, MET amplification, CD44v9 and MUC1. In parallel, advances in synthetic-lethality strategies beyond PARP inhibition and the clinical implementation of ctDNA-based minimal-residual-disease monitoring showcased how molecular profiling and liquid biopsies are reshaping treatment selection and response assessment. Taken together, these developments highlight the growing momentum in biomarker-guided and molecularly driven cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Campus Benjamin Franklin, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, elisabeth.tregel@charite.…
- Charité Comprehensive Cancer Center, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, elisabeth.tregel@charite.de.
- National Center for Tumor Diseases (NCT), NCT Berlin, a partnership between DKFZ, Charité Universitätsmedizin, Berlin Institute of Health at Charité (BIH) and Max Delbrück Center, Berlin, Germany, elisabeth.tregel@chari…
- Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Campus Benjamin Franklin, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Charité Comprehensive Cancer Center, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- National Center for Tumor Diseases (NCT), NCT Berlin, a partnership between DKFZ, Charité Universitätsmedizin, Berlin Institute of Health at Charité (BIH) and Max Delbrück Center, Berlin, Germany.
Zitieren
APA
Tregel, E., Rieke, D. T., Bleckmann, A., Westphalen, C. B., Pretzell, I., Lange, S., Quante, M., & Kloker, L. D. (2026). Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025. Oncology Research and Treatment. https://doi.org/10.1159/000551042
Vancouver
Tregel E, Rieke DT, Bleckmann A, Westphalen CB, Pretzell I, Lange S, et al. Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025. Oncology Research and Treatment. 2026. doi:10.1159/000551042
BibTeX
@article{Tregel2026,
author = {Tregel, Elisabeth and Rieke, Damian T and Bleckmann, Annalen and Westphalen, Christoph Benedikt and Pretzell, Ina and Lange, Sebastian and Quante, Michael and Kloker, Linus D},
title = {Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025},
journal = {Oncology Research and Treatment},
year = {2026},
doi = {10.1159/000551042}
}
EUVIMED